Pneumococcal Vaccine Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Pneumococcal vaccines protect against Streptococcus pneumoniae infections, which cause pneumonia, meningitis, bloodstream infections, and otitis media. The market comprises two main types: pneumococcal conjugate vaccines (PCV) and pneumococcal polysaccharide vaccines (PPV), with PCV representing the dominant segment. Valued at approximately $8.0-8.8 billion in 2023-2025, the market is projected at $9.588 billion in 2026 and is expected to reach between $12.2 billion and $14.4 billion by 2030-2035.

• •PCV drives approximately 91% of global pneumococcal vaccine demand, with PPV accounting for the remaining 9%
• •More than 95% of PCV demand originates from infant vaccination programs
• •The market forms part of the broader global vaccines industry, valued at $50-65 billion in 2025

The primary driver of market growth is the expansion of national immunization programs, particularly in low- and middle-income countries supported by global health initiatives. An aging global population increases demand for adult pneumococcal vaccination, while rising disease awareness and improved healthcare infrastructure in emerging regions broaden market access.

• •WHO and multilateral immunization programs supporting vaccine introduction in eligible countries across Africa, Asia, and Latin America
• •Growing elderly populations driving adult vaccination recommendations across developed and developing markets
• •Increasing prevalence of pneumococcal disease in aging populations and immunocompromised patient groups

The market is strongly skewed toward conjugate vaccines, which account for roughly 91% of total demand. Polysaccharide vaccines, used primarily in adult populations, represent a smaller but established segment. Regional dynamics reflect differences in immunization infrastructure, government spending priorities, and disease burden across income levels.

• •North America and Europe hold significant market share driven by mature immunization programs and adult vaccination recommendations
• •Asia-Pacific and Latin America represent the fastest-growing regions due to expanding PCV introduction and multilateral support programs
• •Infant immunization programs dominate demand, with PCV incorporated into national routine schedules across most upper-middle and high-income countries

Who are the notable companies in the industry?

I can't complete this rewrite as requested. The research text provided contains information exclusively about U.S. Route 69, Interstate 69 in Missouri, and US Highway 69 in Texas, it has zero content related to pneumococcal vaccines, the pharmaceutical industry, or any of the named companies (Serum Institute, CSL, Sanofi, GSK, Merck, Pfizer, Walvax). There are no factual descriptors to draw from. If you have a separate research source covering the pneumococcal vaccine competitive landscape, please provide that and I'll be happy to rewrite the section with the named companies and their factual descriptors.

• •Moderately consolidated market with high barriers to entry due to complex manufacturing processes and stringent regulatory requirements
• •Production involves large-scale bacterial fermentation, polysaccharide purification, and covalent conjugation chemistry requiring specialized expertise
• •Manufacturing capacity concentrated in North America, Europe, and Asia-Pacific, with technology transfer programs expanding production in emerging regions

What are the recent trends and outlook?

The market is expected to sustain a compound annual growth rate of approximately 4.1%, reaching an estimated $12-14 billion range by the early 2030s. Key trends include the development of higher-valency conjugate vaccines covering additional serotypes and ongoing efforts to improve vaccine accessibility in low-resource settings.

• •Development of multi-valent PCV formulations with expanded serotype coverage to address emerging non-vaccine serotypes
• •Technology transfer and local manufacturing initiatives aimed at reducing costs and improving supply security in developing countries
• •Growing emphasis on adult and elderly vaccination programs complementing longstanding infant immunization focus